NBIX
Neurocrine Biosciences
Is NBIX Halal?
Neurological and endocrine disorder treatments with strong compliance.
What You Should Know
Neurocrine develops treatments for neurological, psychiatric, and endocrine disorders. Its March 31, 2026 Form 10-Q reports $4,906.2 million of assets, no reported interest-bearing debt, $266.5 million of cash, $2,380.7 million of available-for-sale debt securities, $768.1 million of receivables and $814.5 million of quarterly revenue. Liquidity/assets is 53.93%, above the examined FTSE, MSCI and Malaysia limits; gross interest income is not separately disclosed, so the quantitative screen fails on liquidity while the core business remains generally permissible.
⚠️ Concerns
- •Available-for-sale debt securities exceed examined liquidity limits
- •Controlled-medication and patient-use questions
- •Clinical research and collaboration agreements
- •Interest income is not separately quantified
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
0 / 4,906.2
2,647.2 / 4,906.2
1,034.6 / 4,906.2
- Financial
- Fails
- Overall
- Fails
Debt/assets is 0.00%, liquidity/assets is 53.93%, above the examined FTSE 33.333% limit, and receivables-plus-cash/assets is 21.09%; gross interest income is unavailable.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 53.93%, above the examined MSCI 33.33% total-assets limit; the liquidity failure is independent of the unavailable income input.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 53.93%, above the examined Malaysia 33% limit; this is a calculation against the named ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Fails
A licensed historical market-cap series is not stored; the liquidity screen fails independently.
Business-activity disclosure
Neurocrine develops and commercializes treatments for neurological, endocrine and psychiatric disorders. The core pharmaceutical activity is generally permissible.
Limitation: The filing does not allocate every product, collaboration, ingredient, controlled-medication or patient end use into a scholar-approved prohibited-revenue numerator.
Purification
Neurocrine reports investment income and other, net but does not separately quantify gross interest income or provide a scholar-approved purification percentage.
Inputs, assumptions and primary sources
- Amounts are USD millions from Neurocrine Biosciences' March 31, 2026 Form 10-Q.
- No interest-bearing debt is reported; operating lease liabilities are excluded.
- Cash is $266.5 million. Current and non-current available-for-sale debt securities total $2,380.7 million and are used as the interest-bearing-securities proxy.
- Accounts receivable are $768.1 million; first-quarter total revenues are $814.5 million.
- The filing reports investment income and other, net of $28.1 million but does not separately quantify gross interest income, so the income input is unavailable.
- Neurological, endocrine and psychiatric medicines are treated as generally permissible; controlled-medication, clinical-trial and patient-use questions require qualitative review.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →